Browse the evidence

Women begin to lose lean mass during menopause, leading to an increase in fat mass.

Practitioners should monitor body composition changes in menopausal women.

Targeted antiobesity medications (AOM) have demonstrated significant weight loss and improved quality of life in patients with specific genetic obesity disorders.

Practitioners should consider targeted AOMs for patients with genetic obesity disorders to improve weight management and quality of life.

Nontargeted AOMs can achieve similar benefits in patients with specific genetic obesity disorders compared to common multifactorial obesity.

Practitioners may consider nontargeted AOMs as an alternative for managing obesity in patients with genetic disorders.

GLP-1RA-induced weight loss would lead to a marked decrease in cancer cases over 10 years in adults.

Implementing GLP-1RA treatments could significantly reduce cancer incidence in obese populations.

If GLP-1RAs were made available for all people with obesity and 50% moved into a lower BMI category, there would be a simulated reduction in cumulative cancer cases of 21,443.

Wider access to GLP-1RAs could lead to significant reductions in cancer cases among obese individuals.

GLP-1 receptor agonists promote glucose-mediated insulin release and are used to treat type 2 diabetes mellitus and obesity.

GLP-1 receptor agonists can be considered for managing type 2 diabetes and obesity in clinical practice.

GLP-1 receptor agonists reduce cardiovascular risk and slow progression to renal failure in persons at high risk and those with type 2 diabetes.

Consider GLP-1 receptor agonists for patients at high risk of cardiovascular issues or renal failure.

Tirzepatide has potential impacts on diabetes, obesity, NASH, and cardiovascular risks.

Tirzepatide may be beneficial for patients with diabetes and associated comorbidities.

Reinitiating semaglutide at the target dose after a treatment gap can lead to adverse effects.

Caution is advised when reinitiating GLP-1 therapy after a gap, especially at target doses.

Therapy lapses with GLP-1 receptor agonists may be prevented by a multi-modal approach.

Implementing a multi-modal strategy can help maintain GLP-1 therapy adherence.

HEC-CG115 reduced fasting blood glucose and glycated haemoglobin levels similar to those after semaglutide.

HEC-CG115 may provide effective glycaemic control for patients with type 2 diabetes.

Tirzepatide achieved MASH resolution with no worsening of fibrosis in a significantly higher percentage of patients than placebo.

Tirzepatide may be a promising treatment option for patients with MASH, potentially improving liver health.

More patients in the tirzepatide group achieved a 1-stage or greater fibrosis improvement without worsening of MASH compared to placebo.

Tirzepatide may help improve liver fibrosis in patients with MASH.

Tirzepatide has been approved for the treatment of adults with type 2 diabetes who are overweight/obese or have weight-related comorbidities.

Tirzepatide is a viable treatment option for managing type 2 diabetes in specific patient populations.

GLP-1 receptor agonists have demonstrated cardioprotection in patients with type 2 diabetes and heart failure.

Incorporating GLP-1RAs into treatment plans may improve cardiovascular outcomes in diabetic patients.

Obesity negatively impacts ovarian stimulation and is associated with reproductive disorders.

Addressing obesity may improve fertility treatment outcomes.

GLP-1 receptor agonists have shown promising results in reducing liver enzymes and improving MASLD.

Practitioners may consider GLP-1 RAs as a therapeutic option for MASLD.

The long-acting GIPR agonist LY3537021 induced a mean body weight loss of 3.14 kg in participants with T2D compared to 0.36 kg in the placebo group at day 57 (p < 0.05).

LY3537021 may be an effective treatment option for weight loss in patients with T2D.

LY3537021 was well tolerated with infrequent gastrointestinal adverse events.

LY3537021 may be a safe option for patients with T2D.

Retatrutide (LY3437943) is a novel triple agonist that targets GLP-1, GIP, and glucagon receptors, representing a transformative advance in obesity pharmacotherapy.

Retatrutide may be considered as a new treatment option for obesity.

Glucagon-like peptide-1 receptor agonists may encourage a more holistic approach to treatment of CKM syndrome.

Clinicians should consider using GLP-1 receptor agonists for integrated treatment strategies.

The efficacy of GLP-1 receptor agonists was consistent across other important subpopulations.

GLP-1 receptor agonists can be considered effective for weight loss across diverse patient groups.

New treatment approaches, including glucagon-like peptide-1 agonists, may be effective for weight loss in pregnant individuals.

Healthcare providers should consider new medical therapies for managing obesity in pregnant individuals.

Insulin therapy often leads to fat mass accumulation and increases the risk of sarcopenic obesity.

Practitioners should be cautious of insulin therapy's potential to increase fat mass and risk of sarcopenic obesity.